| Revision as of 14:20, 14 January 2011 edit209.213.220.109 (talk)No edit summary← Previous edit |
Revision as of 14:05, 19 February 2011 edit undoRjwilmsi (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers932,080 editsm Journal cites:, added 1 PMIDs, completed 1 page ranges, using AWB (7584)Next edit → |
| Line 26: |
Line 26: |
|
}} |
|
}} |
|
|
|
|
|
'''Vorapaxar''' (formerly SCH-530,348) is a ] receptor (]) antagonist based on the natural product ]. Discovered by ] and currently being developed by ], it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061}}</ref> |
|
'''Vorapaxar''' (formerly SCH-530,348) is a ] receptor (]) antagonist based on the natural product ]. Discovered by ] and currently being developed by ], it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061–4|pmid=18447380|issue=11}}</ref> |
|
|
|
|
|
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.<ref>, '']'', January 13, 2011</ref> Merck is uncertain whether further development of vorapaxar will continue. |
|
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.<ref>, '']'', January 13, 2011</ref> Merck is uncertain whether further development of vorapaxar will continue. |
| Line 36: |
Line 36: |
|
* |
|
* |
|
* |
|
* |
|
|
|
|
|
|
|
|
{{Antithrombotics}} |
|
{{Antithrombotics}} |
In January 2011, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions. Merck is uncertain whether further development of vorapaxar will continue.
